Contrasting Orchestra BioMed (NASDAQ:OBIO) & Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ)

Health Sciences Acquisitions Co. 2 (NASDAQ:HSAQ) and Orchestra BioMed (NASDAQ:OBIO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Valuation and Earnings

This table compares Health Sciences Acquisitions Co. 2 and Orchestra BioMed’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Health Sciences Acquisitions Co. 2	N/A	N/A	-$380,000.00	N/A	N/A
Orchestra BioMed	$2.22 million	120.15	-$49.12 million	($1.48)	-5.03

Health Sciences Acquisitions Co. 2 has higher earnings, but lower revenue than Orchestra BioMed.

Analyst Recommendations

This is a summary of current ratings and target prices for Health Sciences Acquisitions Co. 2 and Orchestra BioMed, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Health Sciences Acquisitions Co. 2	0	0	0	0	N/A
Orchestra BioMed	0	0	2	0	3.00

Orchestra BioMed has a consensus target price of $17.00, suggesting a potential upside of 128.49%. Given Orchestra BioMed’s higher probable upside, analysts clearly believe Orchestra BioMed is more favorable than Health Sciences Acquisitions Co. 2.

Risk & Volatility

Health Sciences Acquisitions Co. 2 has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Comparatively, Orchestra BioMed has a beta of 0.41, indicating that its stock price is 59% less volatile than the S&P 500.

Insider & Institutional Ownership

89.7% of Health Sciences Acquisitions Co. 2 shares are owned by institutional investors. Comparatively, 53.5% of Orchestra BioMed shares are owned by institutional investors. 21.9% of Health Sciences Acquisitions Co. 2 shares are owned by company insiders. Comparatively, 6.7% of Orchestra BioMed shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Health Sciences Acquisitions Co. 2 and Orchestra BioMed’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Health Sciences Acquisitions Co. 2	N/A	N/A	-2.38%
Orchestra BioMed	-2,330.46%	-70.18%	-49.17%

Summary

Health Sciences Acquisitions Co. 2 beats Orchestra BioMed on 6 of the 10 factors compared between the two stocks.

About Health Sciences Acquisitions Co. 2

Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.

About Orchestra BioMed

Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.